How Artificial Intelligence is Changing Litigation and Even Preventing it with Arthur Crivella

July 8th, 2021|Categories: Complex Business Litigation, ELP, HB Risk Notes, HB Tort Notes, News, Technology Law|Tags: , , , , |

How Artificial Intelligence is Changing Litigation and Even Preventing it with Arthur Crivella Artificial intelligence has the capability to truly revolutionize how litigators work, and also how companies can avoid litigation in the first place.  It can not only do the work of hundreds of people in mere seconds but can be used to predict liabilities before they become liabilities, and outcomes when disputes arise.  Joining me to discuss the incredible present-day applications of AI in law and business, as well as the potential to do much more if humans will let it, is Arthur Crivella of Crivella Technologies Limited.  For decades Art has been a leader in developing and applying advanced software engineering, systems engineering and AI methodologies, and holds numerous foundation patents in the field.  Art has helped create nationally recognized engineering achievements in weaponry as well as in the metals, rubber and food industries. He was  principal design engineer in developing advanced weapons direction systems and wrap-around simulation systems for naval guided missiles. Crivella Tech supports  corporations in managing  risk and law firms in assessing liabilities. The company also supports law firms in  class action and mass tort litigation. This podcast is the audio companion to the Journal on Emerging Issues in Litigation, a collaborative project between HB Litigation Conferences and the Fastcase legal research family, which includes Full Court Press, Law [...]

Facial Recognition: How It Works and How It Doesn’t

January 14th, 2021|Categories: Class Actions, HB Risk Notes, News, Technology Law|Tags: , , , , |

Debbie Reynolds Founder, CEO & CDPO Debbie Reynolds Consulting Website Martin T. Tully Founding Partner Actuate Law Website Facial Recognition: Benefits & Risks Editor's Note: Imagine how great technology would be if it weren't for people. Since the beginning of time man has developed remarkable solutions to common problems. But leave it to nefarious, despicable, criminal or just plain dumb people to ruin them for the rest of us. You know, like gun powder, nuclear power, and the internet. Facial recognition programs and collection of biometric data would appear to have more benefits than risks, but those risks are there. As use of the technology proliferates we can expect more litigation as additional states follow Illinois -- the first to enact a state Biometric Information Privacy Act. Martin T. Tully of Actuate Law LLC and Debbie Reynolds of Debbie Reynolds Consulting LLC, outline these risks and how regulation and litigation is responding in their article: Facial Recognition Proliferation: Litigation and Legal Implications of Biometric Technologies. Below are a couple excerpts from their article, published in the January 2021 edition of the Journal on Emerging Issues in Litigation. --Tom Hagy Some FR technologies use a scanner to identify 4,500 different points of facial geometry to create a map of a person's face. The application doesn’t [...]

Dr. Babyl: Artificial Intelligence Could Save Lives, Time and Money — TheDailyBeast.com

May 27th, 2019|Categories: Corporate Compliance, HB Risk Notes, Technology Law|Tags: , , , , |

Itchy throat? Headache? Upset stomach? There's an app for that. There is a new AI healthcare system called Babylon UK’s National Health Service which features an AI-driven app that is reportedly able to separate “run-of-the-mill” illnesses from more life-threatening ones, while saving time, money, and anxiety for patients and doctors alike. Babylon offers more than diagnostic assistance; it is accessible to people in remote areas. "For example, Babyl, the Rwandan version of Babylon, offers remote appointments with clinicians, fills prescriptions, orders lab tests, and issues referrals.” Babyl enables affordable, personalized healthcare, combined with “the brains of thousands of doctors at once” to reach patients who cannot get to a doctor’s officer. In addition to assisting doctors with everyday check-ups and treating the common cold, the AI’s abilities extend to clinical trials. “In 2018 the Mayo Clinic partnered with IBM’s Watson to match patients with breast cancer to accessible clinical trials covered by their health plans. The matching program increased the enrollment of breast cancer sufferers in Mayo Clinic’s own clinical trials by 80%." Questions are being raised, however, about how to mitigate risks posed by hacking or by nefarious manipulation of the system. Read about this and more in the complete post by Joelle Renstrom on TheDailyBeast.com. 

Artificial Intelligence: DeepMind on Debugging Learned Predictive Models

May 9th, 2019|Categories: Complex Business Litigation, HB Risk Notes, Technology Law|Tags: , , , , |

DeepMind, an artificial intelligence research company, in a recent blog post discusses three ways to eliminate bugs in learned predictive models. The company was founded in London in 2010. Google acquired it in 2014. In addition to London they have research centers in Edmonton and Montreal, Canada, and a DeepMind Applied team in Mountain View, California. "Bugs and software have gone hand in hand since the beginning of computer programming," the post reads. "Over time, software developers have established a set of best practices for testing and debugging before deployment, but these practices are not suited for modern deep learning systems. Today, the prevailing practice in machine learning is to train a system on a training data set, and then test it on another set. While this reveals the average-case performance of models, it is also crucial to ensure robustness, or acceptably high performance even in the worst case. In this article, we describe three approaches for rigorously identifying and eliminating bugs in learned predictive models: adversarial testing, robust learning, and formal verification." Read the complete post here! 

Mitigating Operational Cyber Risk: As Business Technology Changes, So Does Your Risk Profile

December 6th, 2018|Categories: Corporate Compliance, HB Risk Notes, Technology Law|Tags: , , , , |

By Tom Hagy The various risks of doing business in our digitally connected world continue to evolve.  So must the approach organizations take in confronting those risks, for failing to do so in the current risk landscape can be far more dangerous than in prior years. I spoke with Nick Galletto, Global Cyber Risk Leader at Deloitte, who traced the evolution of the dangers of doing business in a digitally connected world. Early on, our focus in the cyber risk management space was on how to protect websites from being defaced, he explained. Organizations had to make sure websites were functioning properly, that data was secure, and the integrity was maintained. Galletto went on to say that we’ve moved from an era of compliance and risk management to an era of complexity.  From an organization’s perspective, their focus was on making sure the company was compliant with new and evolving regulations, and risk management meant having policies, procedures and effective controls in place. “While compliance is a necessity, it is not the silver bullet that’s going to protect us from any potential breaches," Galletto said. "So organizations must look at conducting their business in this connected world not merely from a compliance perspective but from a risk perspective. A clear example of this is the number of PCI-compliant companies that were still getting breached." “Now as organizations move into an era of complexity, they need to be proactive in detecting anomalies and suspicious behavior and be prepared so their teams have [...]

Oracle Health Sciences on Pharmacovigilance and Artificial Intelligence

August 22nd, 2018|Categories: Complex Business Litigation, HB Risk Notes, HB Tort Notes, Technology Law|Tags: , , , , |

"The potential to use artificial intelligence methods increasingly for the analysis of the increasing amounts of pharmacovigilance data is well understood and many companies are moving (or planning to move) there, and we can predict that routine tasks in pharmacovigilance will in the future be increasingly automated. It will be crucial, however, for regulatory authorities to very clearly provide a position about the use of AI as well as the acceptable level of quality from AI applications. But in parallel with the shaping of those definitions, given the massive increase in their AE case workloads that most companies are currently experiencing, the industry will out of necessity proceed swiftly with the adoption of AI and cloud technologies to reduce their costs and increase their efficiencies. "Like other industries, the pharmaceutical business and in particular the pharmacovigilance field will see a massive change in their processes in the near future, away from tedious, repetitive manual tasks towards a better utilization of scarce resources, in particular medical and scientific knowledge, for value-adding tasks. It is imperative for all stakeholders – industry, service providers and regulators – to provide an environment in which such a transformation can take place without ever compromising public health or the safety of the individual patient, and ideally providing additional benefit for patients." A quote from Addressing the Data [...]

Artificial Intelligence in the Drug and Device Industries

August 9th, 2018|Categories: Complex Business Litigation, HB Tort Notes, Technology Law|Tags: , , , , |

Are Data Divers and Miners Going to Lead Innovation? The big tech companies are into it. Apple, IBM and Google. Roche is into it. Medtronic, as well. Artificial intelligence has been a big part of innovation in the healthcare space for several years, and its impact is only going to get bigger. "Artificial intelligence-based healthcare technologies have contributed to improved drug discoveries, tumor identification, diagnosis, risk assessments, electronic health records (EHR), and mental health tools, among others," writes Blank Rome attorney Brian Higgins in his Artificial Intelligence and the Law Blog (it's excellent, by the way).  [1] Daniel Faggella of TechEmergence.com writes that machine learning healthcare applications are getting a lot of attention in the press and from the investment community. He adds to the list of machine learning's impact things like treatment queries and suggestions, and even robotic surgery. But optimism for AI's application to drug discovery seems greater than that inspired by other healthcare sectors. One reason for that, Faggella writes, is that compared to other segments where various laws and stakeholder incentives may not align, "drug discovery stands out as a relatively straightforward economic value for machine learning healthcare application creators." He adds that this application also involves "one relatively clear customer who happens to generally have deep pockets: drug companies." [2] Also writing for TechEmergence.com, Kumba Sennaa says [...]

McLoughlin on Artificial Intelligence in Banking

July 25th, 2018|Categories: Corporate Compliance, HB Risk Notes, Technology Law|Tags: , , , , |

"Capital adequacy requirements are not the only kind of regulation that AI is helping banks to meet. An even bigger area is monitoring of trading activities for misconduct and abuse. The Bank of England estimates that misconduct by traders has cost banks a global cumulative of $320 billion to date. For this very large reason, banks are aggressively deploying machine learning to monitor the behavior of their traders and detect unusual behavior." Read Michael McLoughlin's post on LinkedIn. Michael McLoughlin is Global Digital Transformation Partner & Advocate with Microsoft.

Halligan, Weyland on Cybersecurity, Trade Secret Asset Management and the Defend Trade Secret Act of 2016

July 23rd, 2018|Categories: Corporate Compliance, HB Risk Notes, Technology Law|Tags: , , , , |

"Cybersecurity protection against outsider theft has largely succeeded, if competently crafted business methods are strictly followed. The more intractable problem of insider theft is now the major concern, and traditional cybersecurity methods are unavailing. The ever-higher digital barriers placed around the corporation and its sensitive data are no defense against data theft by people allowed inside the digital walls in the normal course of business." Read their complete post on LinkedIn. R. Mark Halligan is a Partner and Trial Lawyer at FisherBroyles, LLP. Mr. Halligan has taught Advanced Trade Secrets Law in the John Marshall Law School LLM program for 24 years. Richard F. Weyand is the President of the Trade Secret Office, Inc. www.thetso.com See R. Mark Halligan and Richard F. Weyand Trade Secret Asset Management 2018: A Guide to Information and Asset Management Including RICO and Blockchainavailable on Amazon. https://www.amazon.com/dp/0997070986

RSA’s Zulfikar Ramzan on Blockchain

July 21st, 2018|Categories: Corporate Compliance, HB Risk Notes, Technology Law|Tags: , , , , |

Is blockchain as impenetrable as people think? Or as necessary? It's not predicated on the same type of cryptographic security that we've seen historically, but if someone has enough money and enough motivation -- like a nation state -- couldn't they severely compromise a system? Is blockchain the only way transactional protections can become so secure, or could traditional technologies be employed and with less effort? RSA Security's Chief Technology Officer Zulfikar Ramzan, Ph.D., spoke at our Cyber Sector Risk: Blockchain Security in April 2018 in New York. Hear what he had to say about this much-heralded technology. Related content https://litigationconferences.com/www-litigationconferences-comprivacysecurity-forum-2018-2/ https://litigationconferences.com/international-cyber-risk-management-conference/ https://litigationconferences.com/video-the-urgency-of-cyber-threats-to-u-s-and-global-critical-infrastructures/

Go to Top